UK-based medical technology company Cytox has launched its genetic biomarker research assay variaTECT for research use and to assess Alzheimer’s disease (AD) risk.

The variaTECT single nucleotide polymorphism (SNP) array involves an easy blood-based research test with a comprehensive panel of SNPs indicative of AD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It aids research and novel drug discovery studies while assisting users in the pharmaceutical industry to limit the screening failure rate in detecting amyloid positive subjects for recruitment into clinical trials, thereby saving time and money.

The assay involves a combination of whole exome association analysis, which is the testing of protein-encoding genetic variants across the genome in highly selected and characterised clinical samples, genetic variations and other variants indicative of AD-associated biological pathways.

It has been developed alongside Cytox’s SNPfitR software and polygenic risk score algorithm.

See Also:

"Our studies show the assay has an accuracy of greater than 80%."

Cytox CEO Dr Richard Pither said: “variaTECT is currently the most comprehensive research panel available for the detection of AD informative SNPs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our studies show the assay has an accuracy of greater than 80%, with high-positive and negative predictive values for the amyloid status of test subjects.

“The variaTECT array can be used together with our new SNPfitR software to enrich amyloid-positive cohorts and so reduce screening failure rates in early symptomatic mild cognitive impairment (MCI) and pre-symptomatic subject groups.”

The research array will be commercialised as the Axiom Dementia Research Array which is comprised of the variaTECT SNP panel designed on an Affymetrix Axiom Genotyping Array and processed on an Affymetrix GeneTitan Multi-Channel Instrument.